2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.PMID:
20610543.
3. Burt RW. Colorectal cancer screening. Curr Opin Gastroenterol 2010;26:466-470.PMID:
20664346.
4. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy: the National Polyp Study Workgroup. N Engl J Med 1993;329:1977-1981.PMID:
8247072.
5. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004;287:G7-G17.PMID:
15194558.
6. Maggio-Price L, Treuting P, Zeng W, Tsang M, Bielefeldt-Ohmann H, Iritani BM. Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. Cancer Res 2006;66:828-838.PMID:
16424015.
7. Sansbury LB, Millikan RC, Schroeder JC, Moorman PG, North KE, Sandler RS. Use of nonsteroidal antiinflammatory drugs and risk of colon cancer in a population-based, case-control study of African Americans and Whites. Am J Epidemiol 2005;162:548-558.PMID:
16093288.
8. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-899.PMID:
12621133.
9. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-890.PMID:
12621132.
10. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-1316.PMID:
8385741.
11. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635-639.PMID:
1650315.
12. Ladenheim J, Garcia G, Titzer D, et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology 1995;108:1083-1087.PMID:
7698575.
13. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.PMID:
10874062.
14. Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 2008;123:1133-1140.PMID:
18528865.
16. Toriola AT, Cheng TY, Neuhouser ML, et al. Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers. Int J Cancer 2013;132:2648-2658.PMID:
23161620.
17. Chiu HM, Lin JT, Chen TH, et al. Elevation of C-reactive protein level is associated with synchronous and advanced colorectal neoplasm in men. Am J Gastroenterol 2008;103:2317-2325.PMID:
18844617.
18. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004;291:585-590.PMID:
14762037.
19. Rhodes JM, Campbell BJ. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med 2002;8:10-16.PMID:
11796261.
20. Crockett SD, Mott LA, Barry EL, et al. C-reactive protein and risk of colorectal adenomas or serrated polyps: a prospective study. Cancer Prev Res (Phila) 2014;7:1122-1127.PMID:
25145487.
21. Gunter MJ, Cross AJ, Huang WY, et al. A prospective evaluation of C-reactive protein levels and colorectal adenoma development. Cancer Epidemiol Biomarkers Prev 2011;20:537-544.PMID:
21212059.
22. Park SK, Park DI, Park JH, et al. C-reactive protein level and colorectal adenoma. Korean J Gastroenterol 2008;51:225-231.PMID:
18516001.
23. Ito Y, Suzuki K, Tamakoshi K, et al. Colorectal cancer and serum C-reactive protein levels: a case-control study nested in the JACC Study. J Epidemiol 2005;15(Suppl 2): S185-S189.PMID:
16127232.
24. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on colorectal cancer. Gastroenterology 2012;143:844-857.PMID:
22763141.
25. Rogowski O, Zeltser D, Shapira I, et al. Gender difference in C-reactive protein concentrations in individuals with atherothrombotic risk factors and apparently healthy ones. Biomarkers 2004;9:85-92.PMID:
15204313.
26. Otake T, Uezono K, Takahashi R, et al. C-reactive protein and colorectal adenomas: Self Defense Forces Health Study. Cancer Sci 2009;100:709-714.PMID:
19469014.
27. Kim S, Keku TO, Martin C, et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res 2008;68:323-328.PMID:
18172326.
28. Tsilidis KK, Erlinger TP, Rifai N, et al. C-reactive protein and colorectal adenoma in the CLUE II cohort. Cancer Causes Control 2008;19:559-567.PMID:
18214695.
29. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115:911-919.PMID:
15867843.
30. Kawada T. Relationships between the smoking status and plasma fibrinogen, white blood cell count and serum C-reactive protein in Japanese workers. Diabetes Metab Syndr 2015;9:180-182.PMID:
25801482.
31. Longo-Mbenza B, Nkongo Mvindu H, Kasiam On’kin JB, et al. The deleterious effects of physical inactivity on elements of insulin resistance and metabolic syndrome in Central Africans at high cardiovascular risk. Diabetes Metab Syndr 2011;5:1-6.PMID:
22814833.
32. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-334.PMID:
11466099.
33. Effoe VS, Correa A, Chen H, Lacy ME, Bertoni AG. High-sensitivity C-reactive protein is associated with incident type 2 diabetes among African Americans: the Jackson Heart Study. Diabetes Care 2015;38:1694-1700.PMID:
26068864.
34. Rampal S, Yang MH, Sung J, et al. Association between markers of glucose metabolism and risk of colorectal adenoma. Gastroenterology 2014;147:78-87.PMID:
24632359.
35. Kang HW, Kim D, Kim HJ, et al. Visceral obesity and insulin resistance as risk factors for colorectal adenoma: a cross-sectional, case-control study. Am J Gastroenterol 2010;105:178-187.PMID:
19755965.
36. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565.PMID:
12432042.
37. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003;290:2945-2951.PMID:
14665655.
38. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001;47:444-450.PMID:
11238295.
39. Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 2001;47:426-430.PMID:
11238292.